somatostatin analogs (Neoprobe)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namesomatostatin analogs (Neoprobe)
Drug Alias Namesomatostatin octapeptides (Neoprobe)RIGS somatostatin analogs (Neoprobe)
ClassificationBiologics > Protein drugs > Recombinant polypeptideDiagnostic agent (In vivo)
Mechanisms of ActionSomatostatin receptor agonists
TargetsSomatostatin receptor
Therapy Area/IndicationsEndocrine Gland NeoplasmsBreast NeoplasmsNeuroendocrine Tumors +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNavidea Biopharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNavidea Biopharmaceuticals IncThe Ohio State UniversityIpsen Bioscience Inc
Active IndicationsN/A
Inactive IndicationsEndocrine Gland NeoplasmsBreast NeoplasmsNeuroendocrine Tumors +[4] 

Other Information

ATC CodeN/A
Related LinksN/A